LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
42,935
63,209
90,335
83,337
130,014
Cost of Revenue
3,000
2,491
1,899
-
0
Gross Profit
39,935
60,718
88,436
-
130,014
Operating Expenses
Research Development
50,729
100,243
156,813
178,151
95,187
Selling General and Administrative
60,515
63,754
66,203
43,044
23,835
Total Operating Expenses
111,244
163,997
223,016
221,195
119,022
Operating Income or Loss
-71,309
-103,279
-134,580
-137,858
10,992
Interest Expense
20,758
20,777
6,984
6,567
6,722
Total Other Income/Expenses Net
-
-
-2,101
703
-9,524
Income Before Tax
-88,994
-120,548
-141,711
-141,429
-4,682
Income Tax Expense
-
0
-12,661
0
0
Income from Continuing Operations
-88,994
-120,548
-129,050
-141,429
-4,682
Net Income
-88,994
-120,548
-129,050
-141,429
-4,682
Net Income available to common shareholders
-88,994
-120,548
-129,050
-141,429
-4,682
Reported EPS
Basic
-
-1.14
-1.23
-1.36
-0.05
Diluted
-
-1.14
-1.23
-1.36
-0.05
Weighted average shares outstanding
Basic
-
105,830
105,237
103,863
103,591
Diluted
-
105,830
105,237
103,863
103,591
EBITDA
-
-99,771
-134,727
-134,862
2,040